Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Nat Rev Cancer. 2011 Jul 14;11(8):541-57. doi: 10.1038/nrc3087.

Advances in sarcoma genomics and new therapeutic targets.

Author information

  • 1Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.

Erratum in

  • Nat Rev Cancer. 2011;11(9):685.

Abstract

Increasingly, human mesenchymal malignancies are being classified by the abnormalities that drive their pathogenesis. Although many of these aberrations are highly prevalent within particular sarcoma subtypes, few are currently targeted therapeutically. Indeed, most subtypes of sarcoma are still treated with traditional therapeutic modalities, and in many cases sarcomas are resistant to adjuvant therapies. In this Review, we discuss the core molecular determinants of sarcomagenesis and emphasize the emerging genomic and functional genetic approaches that, coupled with novel therapeutic strategies, have the potential to transform the care of patients with sarcoma.

PMID:
21753790
[PubMed - indexed for MEDLINE]
PMCID:
PMC3361898
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group Icon for PubMed Central
    Loading ...
    Write to the Help Desk